Olmetec and Diabetic nephropathy - a phase IV clinical study of FDA data

Summary:

Diabetic nephropathy is reported as a side effect among people who take Olmetec (olmesartan medoxomil), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Januvia, and have Type 2 diabetes.

The phase IV clinical study analyzes which people have Diabetic nephropathy when taking Olmetec. It is created by eHealthMe based on reports of 7,816 people who have side effects when taking Olmetec from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Diabetic nephropathy?

Diabetic nephropathy (diabetic kidney disease) is found to be associated with 437 drugs and 603 conditions by eHealthMe. Check the latest studies of Diabetic nephropathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

7,816 people reported to have side effects when taking Olmetec.
Among them, 17 people (0.22%) have Diabetic nephropathy.

Could Olmetec cause Diabetic nephropathy?

Among these 17 people:

How long have people been on Olmetec when they have Diabetic nephropathy? *

What is the gender of people who have Diabetic nephropathy when taking Olmetec? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Diabetic nephropathy when taking Olmetec? *

What are other drugs people take besides Olmetec? *

What are other side effects people have besides Diabetic nephropathy? *

Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 3 people, 17.65%
Acute Myocardial Infarction (acute heart attack): 2 people, 11.76%
Anaemia (lack of blood): 2 people, 11.76%
Death: 2 people, 11.76%
Nasopharyngitis (inflammation of the nasopharynx): 2 people, 11.76%
Blood Pressure Abnormal: 1 person, 5.88%
Coronary Artery Stenosis (narrowing of coronary artery): 1 person, 5.88%
Concomitant Disease Aggravated (advanced due to some of accompanying): 1 person, 5.88%
Chronic Renal Failure (kidney failure): 1 person, 5.88%
Chills (felling of cold): 1 person, 5.88%

What are the existing conditions these people have? *

Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 3 people, 17.65%
Type 2 Diabetes: 3 people, 17.65%
Constipation: 2 people, 11.76%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 2 people, 11.76%
Nephrogenic Anaemia (anaemia due to kidney disease): 2 people, 11.76%
Diabetes: 1 person, 5.88%
Essential Hypertension (primary hypertension): 1 person, 5.88%
Gastric Ulcer (stomach ulcer): 1 person, 5.88%
Gastritis (inflammation of stomach): 1 person, 5.88%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and have Diabetic nephropathy?

- Check whether Diabetic nephropathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olmetec:

Olmetec (7,904 reports)

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diabetic nephropathy:

Diabetic nephropathy (437 drugs)

Browse all the conditions that are associated with Diabetic nephropathy:

Diabetic nephropathy (603 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Olmetec) and Olmetec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.